Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ventyx Biosciences Inc (NQ: VTYX )

2.150 -0.010 (-0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ventyx Biosciences Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
Analyst Ratings for Ventyx Biosciences
Via Benzinga
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive
JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Shares of Ventyx Biosciences Rose Monday
The company has several promising autoimmune therapies. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share. 
Via Benzinga
US Stocks Mixed; Dow Falls Over 50 Points
U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%... 
Via Benzinga
6 Analysts Have This to Say About Ventyx Biosciences
Via Benzinga
The Latest Analyst Ratings for Ventyx Biosciences
Via Benzinga
Recap: Ventyx Biosciences Q1 Earnings
Via Benzinga
Preview: Ventyx Biosciences's Earnings
Via Benzinga
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
Ventyx Biosciences's Earnings Outlook
Via Benzinga
Analyst Expectations for Ventyx Biosciences's Future
Via Benzinga
Expert Ratings for Ventyx Biosciences
Via Benzinga
6 Analysts Have This to Say About Ventyx Biosciences
Via Benzinga
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million. 
Via Benzinga
Earnings Outlook For Ventyx Biosciences
Ventyx Biosciences (NASDAQ:VTYX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Ventyx... 
Via Benzinga
Stifel Maintains Buy Rating for Ventyx Biosciences: Here's What You Need To Know
Stifel has decided to maintain its Buy rating of Ventyx Biosciences (NASDAQ:VTYX) and raise its price target from $45.00 to $53.00. Shares of Ventyx Biosciences are trading up 4.1% over the last 24... 
Via Benzinga
Dow To $45? Here Are 5 Other Price Target Changes For Tuesday
Jefferies cut the price target on Dow Inc. (NYSE: DOW) from $71 to $45. Jefferies analyst Laurence Alexander also downgraded the stock from Buy to Hold. Dow shares fell 0.8% to $50.55 in pre-market... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.